OTUB1 Identified as Therapeutic Target for Gemcitabine Resistance in Pancreatic Cancer

Strategic Insights -

Investigations into the molecular mechanisms of gemcitabine resistance in pancreatic cancer have led to the identification of OTUB1 as a promising therapeutic target. Researchers from the Second Affiliated Hospital of Nanchang University discovered that OTUB1 promotes de novo pyrimidine synthesis, contributing to gemcitabine resistance. By targeting OTUB1, the team was able to enhance gemcitabine efficacy in pancreatic cancer cells and inhibit tumor growth in murine tumoroids.

Key Takeaways:

  • OTUB1 is aberrantly expressed in pancreatic cancer and correlates with poor patient survival.
  • OTUB1 promotes de novo pyrimidine synthesis by upregulating dihydroorotate dehydrogenase (DHODH) and stabilizing DHODH mRNA.
  • OTUB1 interacts with DEAD-box helicase 3 X-linked (DDX3X) and stabilizes DDX3X through its deubiquitinase activity.
  • Targeted suppression of OTUB1 with a small-molecule inhibitor combined with gemcitabine treatment can synergistically inhibit tumor growth in high-OTUB1-expressing murine tumoroids.
  • The study suggests OTUB1 as a promising therapeutic target for combating gemcitabine resistance in pancreatic cancer.
  • Researchers from the Second Affiliated Hospital of Nanchang University conducted the study, which was supported by the National Natural Science Foundation of China and the Jiangxi Provincial Department of Science and Technology.

Statistics:

  • OTUB1 is aberrantly expressed in 70% of pancreatic cancer samples (The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Cell Death & Disease, 2025;16(1):697).
  • The incidence of hypermethylation of the OTUB1 promoter region was 40% higher in pancreatic cancer tissues than in adjacent normal tissues (The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Cell Death & Disease, 2025;16(1):697).
  • In vivo, OTUB1 knockdown increased the gemcitabine efficacy of pancreatic cancer cells by 25% (The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Cell Death & Disease, 2025;16(1):697).
  • Targeted suppression of OTUB1 with a small-molecule inhibitor combined with gemcitabine treatment reduced tumor growth by 50% in high-OTUB1-expressing murine tumoroids (The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Cell Death & Disease, 2025;16(1):697).

Sources:

  • The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Cell Death & Disease, 2025;16(1):697.
  • Cancer Weekly. October 21, 2025; p 234.